Impacto del SARS-COV-2 en pacientes con enfermedad inflamatoria intestinal

Abstract

Introduction: Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal system that includes conditions such as Crohn's disease and ulcerative colitis. Patients often require immunosuppressive and biological treatments to control the illness. With the emergence of the COVID-19 pandemic caused by the SARS-CoV-2 virus, particular concern arose about how this infection could affect people with IBD and whether immunosuppressive treatments could increase their vulnerability. Objective: To establish, through scientific articles, the impact of COVID-19 on patients with Inflammatory bowel diseases. Methodology: Narrative literature review. Results: IBD patients do not appear to be at increased risk of contracting SARS-CoV-2 infection compared to the general population. However, those who develop COVID-19 may be at increased risk of serious complications, especially if they are undergoing immunosuppressive treatment. Risk factors associated with COVID-19 in IBD patients include older age, the presence of comorbidities, and the use of medications such as high-dose corticosteroids. Diarrhea is a common symptom in patients with IBD and COVID-19, and in some cases, it may be the only symptom at the onset of infection. Gastrointestinal symptoms can mimic an IBD relapse. Conclusions: IBD patients do not appear to have a higher risk of contracting SARS-CoV-2 infection compared to the general population, but they have an increased risk of complications associated with the drugs used.